Profusa (NASDAQ:PFSA) has signed a non-binding term sheet to acquire a commercial-stage diagnostics company with estimated 2025 net revenue of approximately $111 million, while also reshaping its executive leadership as it pivots toward a diagnostics-focused business model.
Key Investor Takeaways
- Profusa (NASDAQ:PFSA) signed a non-binding term sheet to acquire a commercial-stage diagnostics company.
- The target company estimates approximately $111 million in unaudited 2025 net revenue.
- The combined business is expected to operate as a public diagnostics company with recurring revenue and national CLIA-certified laboratories.
- Profusa appointed Jack Stover as Executive Chairman and Chief Executive Officer, while former CEO Ben Hwang became President.
- The company expects to secure approximately $7 million in financing alongside the proposed transaction.
Why PFSA Stock Is In Focus
Profusa announced it has entered into a non-binding term sheet to acquire a privately held health diagnostics and toxicology testing company. If completed, the transaction would transform Profusa into a publicly traded diagnostics company operating national CLIA-certified laboratories serving addiction treatment, pain management, and behavioral health providers.
According to management, the acquisition target generated estimated unaudited net revenue of approximately $111 million during 2025.
The proposed consideration includes Profusa issuing common stock equal to 19.99% of its outstanding shares at closing, with the remaining consideration paid through non-voting convertible preferred stock that would require shareholder approval before conversion into common shares. The company also expects its outstanding convertible notes and other obligations to be exchanged for preferred stock.
Alongside the proposed acquisition, Profusa announced significant leadership changes. Director Jack Stover has been appointed Executive Chairman and Chief Executive Officer, replacing Ben Hwang, who will now serve as President. The company also appointed Liviu Goldenberg as an independent director.
Why This Matters For Investors
The proposed acquisition signals a potential strategic shift from Profusa’s biosensor development business toward an operating diagnostics platform with established commercial operations and recurring revenue. If completed, the transaction could significantly change the company’s business profile by adding an operating business with meaningful revenue rather than relying primarily on product development.
The financing structure also deserves attention. In addition to issuing common and preferred equity, Profusa expects to raise approximately $7 million through convertible notes to support the transaction. Investors may monitor the potential impact of these financing arrangements and future share issuance on the company’s capital structure.
However, the transaction remains at an early stage. The agreement is currently non-binding, and completion remains subject to due diligence, definitive documentation, financing, and other customary closing conditions.
What to Watch Next
Investors will likely monitor:
- Execution of a definitive acquisition agreement.
- Completion of due diligence and satisfaction of closing conditions.
- Final financing terms and the anticipated $7 million convertible note offering.
- Shareholder approval related to the proposed preferred stock conversion.
- Further details on the financial performance and integration plans for the diagnostics business if the acquisition proceeds.